West Michigan Rheumatology was one of the original investigational sites for Enbrel – the first biologic approved for use in psoriatic arthritis.  We also performed the early phase 1 and studies of Brodalumab (a monoclonal antibody directed against interleuken-17) in rheumatoid arthritis.  Subsequently we conducted several clinical trials of its effectiveness and safety in patients with Psoriatic Arthritis. Our participation evaluating this novel therapeutic target is an extension of this series of investigations and shows our committment to helping explore the possible conditions that could potentially benefit from targeted biologic therapy, including psoriatic arthritis.  

 Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Whitmore JB.  J Rheumatol. 2004 Jul;31(7):1356-61.

We have also developed, evaluated and nationally disseminated a novel Option Table Decision Aid for dermatologists and rheumatologists to use to support their conversations with patients with psoriatic arthritis considering a new immunomodulator.